According to filings with the U.S. Securities and Exchange Commission, TYBR Health is raising up to $30 Million in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About TYBR Health
TYBR Health is a medical technology and regenerative medicine company that focuses on transforming the post-operative recovery experience by developing advanced biomaterial therapies to protect healing tissues after surgery. Centered on orthopedic applications, the company is creating natural, hydrogel-based solutions designed to safeguard tendons and ligaments, reduce complications from scarring, and support functional restoration so patients can return to daily activities more quickly. TYBR Health positions itself as an innovator in post-surgical care, aiming to work with the bodys natural biology rather than relying on synthetic materials, and emphasizes improving surgical outcomes, simplifying recovery, and enhancing quality of life through better soft-tissue protection. The company highlights its commitment to collaboration with surgeons and its vision to redefine what recovery means by streamlining healing and optimizing patient recovery using cutting-edge biomaterial technologies. Operating through its website as an information hub, TYBR Health underscores that its products are still under development and not yet commercially available, reinforcing its status as an emerging player focused on research-driven solutions in the post-surgical recovery market.

To learn more, visit https://www.tybrhealth.com/
LinkedIn: https://www.linkedin.com/company/tybr-health

Contact:
Timothy Keane, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.